Realizing a new life with diabetes.
Diasome is pioneering a transformative cell receptor drug targeting platform.
For the first time ever, Diasome is bringing together liver physiology and diabetes pharmaceuticals so that people can realize a new way of life.
01
Science with Intent
Diasome’s novel cell targeting platform illuminates fundamental understandings of diabetes, one of the world’s fastest growing diseases.
Our Purpose with Diasome’s CEO, Robert Geho.
02
The Diabetes Challenge
Outcomes in diabetes are not improving.
With over 10 classes of drugs and 10 different insulins, anti-diabetic medications make up the largest annual revenue generating drug category in the U.S. More Americans die from diabetes every year than from AIDS and breast cancer combined.
The Stats on Type 1 Diabetes
1.6 million people in the U.S. are living with Type 1 Diabetes.
5 million people are expected to have T1D by 2050, including nearly 600,000 youth.
A1C levels aren’t improving for Type 1 Diabetes.
Mean A1C levels jumped from 7.8% to 8.4% over an 8 year period (2010 – 2018).
The Stats on Type 2 Diabetes
Roughly 32.3 million people, or 9.2% of the U.S. population, is diagnosed with Type 2 Diabetes.
An estimated 88 million adults aged 18 years or older had prediabetes in 2018.
50% of people in the U.S. with Type 2 diabetes have an A1C value of 7.0% or higher.
The Economic Burden of Diabetes
The estimated national cost of diabetes in 2017 was $327 billion.
Diabetes accounts for 1 in 4 healthcare dollars spent in the U.S. Care for a person with diabetes now costs an average of $16,752 per year.
Hypoglycemia is the major limiting factor in the glycemic management of Type 1 and Type 2 diabetes.
American Diabetes Association
03
A Common Solution
Engaging the liver is vital for preventing hypoglycemia.
01
“It is impossible to normalize the glucose distribution between the liver and muscle when regular insulin is administered peripherally.”
02
“The overdose of peripheral insulin required to compensate for the effects of its under-replacement at the liver markedly increases the risk of hypoglycemia.”
03
“Glucose metabolism could be fully normalized by a hepato (liver)-preferential insulin.”
Novo Nordisk
JCI Insight. 2019;4(7):e126974.
RESTORING PHYSIOLOGY
The Liver’s Unique Function
Current insulins fail to reach the liver as insulin does in people without diabetes, markedly increasing the risk of hypoglycemia.
01
The liver is the only organ that stores and releases glucose.
02
In normal physiology, liver glucose storage prevents high blood sugar, liver glucose release prevents low blood sugar.
03
HDV delivers critical drugs like insulin to restore liver physiology.
04
By restoring liver physiology, we prevent hypoglycemia and allow insulin requiring people to pursue glycemic control more aggressively.
04
Hepatic Drug Delivery
Diasome is the only company in diabetes drug development that is targeting the body’s own glucose control center to prevent hypoglycemia and help normalize blood glucose for people with diabetes.
The challenge with current insulins and how HDV-Insulin restores the liver's natural ability to store and release glucose with Diasome's Chief Medical Officer, Marc Penn, M.D., PhD
Breakthrough HDV Technology
Improving diabetes outcomes with HDV.
01
HDV is 50 Nanometers in diameter.
HDV is a nanoscale, frisbee-shaped carrier that can be customized to target payloads to the liver, whether injected or taken orally.
02
Biotin is used to target the liver.
HDV is designed to be accepted and removed by the liver through normal liver metabolism.
03
Each disc delivers approximately 100 insulin molecules to the liver.
HDV can be used as an admix or premixed with any commercially available insulin and therefore is compatible with any delivery method, including insulin pump systems.
04
Diasome Pipeline
A portfolio designed to meet patient needs.
Preclinical
Oral HDV PF-1 for T2D
Phase 2
Injectable HDV Basal Insulin for T1D and T2D
Phase 2B
Injectable HDV Mealtime Insulin for T1D: Ph 2b Estimated Q1 2023 Start
Oral HDV Insulin
